Emmaus 2023 revenue up 61% to $29.6M, net loss narrows to $3.7M

Emmaus Life Sciences, Inc.

2024-Q2 EPS reported -$0.10 revenue$7,883,000

Net revenue $29.6M (vs $18.4M in 2022); operating income $3.5M vs loss $6.6M.
Net loss $3.7M ($0.07/sh) vs $10.6M ($0.21/sh); cash $2.5M at Dec 31, 2023.
MENA region and U.S. sales drove growth; disposed of Japanese JV equity interest.
Inventory shortage impacted Q4 2023 sales; backlog ~$4.6M as of May 24, 2024; now resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.